Goldman Sachs Slams Omicron Panic: ‘Mutation Is Unlikely to Be More Malicious’

This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2, yellow, emerging from the surface of cells, blue/pink, cultured in the lab. Also known as 2019-nCoV, the virus causes COVID-19. NIAID-RML/AP/The Canadian Press

Investment bank Goldman Sachs has asserted that concerns over the COVID-19 Omicron variant likely are unfounded.

“This mutation is unlikely to be more malicious and ... the existing vaccines will most likely continue to be effective in preventing hospitalizations and deaths,” Goldman said in a Nov. 26 note. “We do not think that the new variant is sufficient reason to make major portfolio changes.”